Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Lumosa Therapeutics Co Ltd (6535)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
142.00 +7.00    +5.19%
07/08 - Closed. Currency in TWD
Type:  Equity
Market:  Taiwan
ISIN:  TW0006535008 
  • Volume: 562,845
  • Bid/Ask: 35.45 / 35.50
  • Day's Range: 134.50 - 146.50
Lumosa Therapeutics 142.00 +7.00 +5.19%

Lumosa Therapeutics Co Ltd Company Profile

 
Get an in-depth profile of Lumosa Therapeutics Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

47

Equity Type

ORD

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.

Contact Information

Address No. 3-2, Park Street 4th Floor
Nangang District Taipei, 11503
Taiwan
Phone 886 2 2655 7918
Fax 886 2 2655 7919

Top Executives

Name Age Since Title
Fang Wei Ding - - Member of the Supervisory Board
Xue Ling Wang - - Director
Wan-Lai Cheng - - Director
Hsueh-Lin Wang - - Independent Director
Hai I Ma - 2021 Independent Director
Chih-Hsiung Wu - - Independent Director
Zhixiong Wu - - Independent Director
Xinrong Lin - - Independent Director
De-Fu Hsieh - 2025 Representative Director
Chia-Ling Lin - 2024 Representative Director
Xie Defu - - Director
Shinn-Zong Lin - 2025 Independent Director
Su-Chi Wang - 2024 Chairman of the Board
Chih Yung Chin 62 - Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

6535 Comments

Write your thoughts about Lumosa Therapeutics Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email